InsidersTradesSigma
Total declarations
Companies
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by GOEDDEL DAVID V, Director. Officer active across 2 companies, notably Tenaya Therapeutics, Inc.. In total, 14 reports have been recorded. Total volume traded: €16.7m. The latest transaction was filed on 9 June 2022 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations14 total
€12m951,684 shares@ €12.712872.4% of flow
Common Stock
SEC:0000899243-22-022210:0·
Ideal exit: 6 Mar 2023 (T+270)
€400,91333,071 shares@ €12.12282.4% of flow
Common Stock
SEC:0000899243-22-021211:0·
Ideal exit: 27 Feb 2023 (T+270)
€749,75759,766 shares@ €12.54494.5% of flow
Common Stock
SEC:0000899243-22-020683:0·
Ideal exit: 25 Feb 2023 (T+270)
€245,58219,534 shares@ €12.5721.5% of flow
Common Stock
SEC:0000899243-22-020199:0·
Ideal exit: 20 Feb 2023 (T+270)
€214,65417,240 shares@ €12.4511.3% of flow
Common Stock
SEC:0000899243-22-019685:0·
Ideal exit: 18 Feb 2023 (T+270)
€250,38519,984 shares@ €12.52931.5% of flow
Common Stock
SEC:0000899243-22-019205:0·
Ideal exit: 13 Feb 2023 (T+270)
€1m86,110 shares@ €12.72026.6% of flow
Common Stock
SEC:0000899243-22-018846:0·
Ideal exit: 11 Feb 2023 (T+270)
125,096 shares
Common Stock
SEC:0000899243-22-018397:0·
Ideal exit: 7 Feb 2023 (T+270)
€831,49577,866 shares@ €10.67855.0% of flow
Common Stock
SEC:0000899243-22-018029:0·
Ideal exit: 5 Feb 2023 (T+270)
€821,58880,430 shares@ €10.21494.9% of flow
Common Stock
SEC:0000899243-22-017671:0·
Ideal exit: 3 Feb 2023 (T+270)
241,750 shares
Common Stock
SEC:0000899243-22-003314·
Ideal exit: 21 Oct 2022 (T+270)
241,750 shares
Common Stock
SEC:0000899243-22-003314:0·
Ideal exit: 21 Oct 2022 (T+270)
04,389,282 shares0
Common Stock
SEC:0001209191-21-049762·
04,389,282 shares0
Common Stock
SEC:0001209191-21-049762:0·
14 of 14 declarations
About GOEDDEL DAVID V
David V. Goeddel is a Board Member at Tenaya Therapeutics, Inc. and NGM Biopharmaceuticals Inc. In this role, he participates in the governance of the companies and strategic decision-making. David V. Goeddel brings valuable expertise in the biotechnology field, supporting innovation and the development of new treatments. His commitment to excellence and corporate responsibility is an asset to the boards.
